Free Trial
→ GENIUS Act: The Plot to Seize Your Cash? (From Priority Gold) (Ad)tc pixel

Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Up 17.3% - Here's Why

Written by MarketBeat
September 10, 2025
Sino Biopharmaceutical logo with Medical background

Key Points

  • Sino Biopharmaceutical shares surged by 17.3% during trading, reaching a high of $1.16, with a trading volume increase of 2,964% compared to the average session.
  • The stock's 50-day moving average is at $0.90 and its 200-day moving average is at $0.64, indicating significant upward momentum.
  • Sino Biopharmaceutical operates as a major pharmaceutical conglomerate in China, focusing on various segments including oncology and liver disease medications.
  • Five stocks we like better than Sino Biopharmaceutical.

Shares of Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) shot up 17.3% during mid-day trading on Monday . The company traded as high as $1.16 and last traded at $1.16. 2,500 shares were traded during trading, an increase of 2,964% from the average session volume of 82 shares. The stock had previously closed at $0.99.

Sino Biopharmaceutical Stock Performance

The stock's 50-day moving average is $0.90 and its 200-day moving average is $0.64.

Sino Biopharmaceutical Company Profile

(Get Free Report)

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sino Biopharmaceutical Right Now?

Before you consider Sino Biopharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sino Biopharmaceutical wasn't on the list.

While Sino Biopharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.